$GHSI
Guardion Health Sciences Inc

2022 Q4 Form 10-Q Financial Statement

#000149315222031624 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $2.726M $2.664M $3.149M
YoY Change 3.76% -15.41% 1159.44%
Cost Of Revenue $1.790M $1.575M $1.761M
YoY Change 14.47% -10.52% 1500.54%
Gross Profit $936.2K $1.088M $1.388M
YoY Change -11.98% -21.6% 891.44%
Gross Profit Margin 34.34% 40.85% 44.08%
Selling, General & Admin $2.188M $2.758M $4.075M
YoY Change -41.27% -32.32% 81.93%
% of Gross Profit 233.75% 253.46% 293.6%
Research & Development $31.38K $60.20K $16.23K
YoY Change 191.64% 270.94% -45.9%
% of Gross Profit 3.35% 5.53% 1.17%
Depreciation & Amortization $302.4K $14.72K $317.5K
YoY Change -7.0% -95.36%
% of Gross Profit 32.3% 1.35% 22.87%
Operating Expenses $2.220M $2.828M $4.091M
YoY Change -40.6% -30.89% 80.24%
Operating Profit -$1.284M -$1.739M -$2.703M
YoY Change -51.99% -35.66% 26.92%
Interest Expense $2.444M $43.28K
YoY Change 284075.58%
% of Operating Profit
Other Income/Expense, Net $2.346M $916.5K $0.00
YoY Change -100.0%
Pretax Income -$8.906M -$1.696M -$3.015M
YoY Change -38.67% -43.74% 40.88%
Income Tax
% Of Pretax Income
Net Earnings -$9.847M -$1.696M -$3.015M
YoY Change -32.18% -43.74% 40.88%
Net Earnings / Revenue -361.18% -63.68% -95.75%
Basic Earnings Per Share -$0.03 -$0.12
Diluted Earnings Per Share -$7.99 -$27.53K -$123.4K
COMMON SHARES
Basic Shares Outstanding 61.60M shares 61.60M shares 24.43M shares
Diluted Shares Outstanding 1.232M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.91M $12.95M $10.56M
YoY Change 74.99% 22.61% 7.74%
Cash & Equivalents $10.66M $12.95M $3.564M
Short-Term Investments $0.00 $0.00 $6.995M
Other Short-Term Assets $687.9K $1.038M $1.247M
YoY Change -42.69% -16.71% 442.05%
Inventory $3.119M $1.953M $792.6K
Prepaid Expenses $1.038M
Receivables $1.924M $1.874M $2.269M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $21.64M $17.81M $14.87M
YoY Change 79.28% 19.81% 31.21%
LONG-TERM ASSETS
Property, Plant & Equipment $48.87K $53.76K $298.8K
YoY Change -56.12% -82.01% -60.69%
Goodwill
YoY Change
Intangibles $0.00 $10.36M
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets $1.280K
YoY Change -87.2%
Total Long-Term Assets $48.87K $10.42M $23.75M
YoY Change -99.57% -56.13% 2761.03%
TOTAL ASSETS
Total Short-Term Assets $21.64M $17.81M $14.87M
Total Long-Term Assets $48.87K $10.42M $23.75M
Total Assets $21.69M $28.23M $38.61M
YoY Change -7.56% -26.89% 217.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.518M $1.041M $1.183M
YoY Change 528.99% -12.03% 103.96%
Accrued Expenses $558.3K $683.2K $787.2K
YoY Change -37.65% -13.21% 131.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.012M $1.733M $1.970M
YoY Change 246.11% -12.02% 69.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.507M $0.00 $0.00
YoY Change 118183.46% -100.0%
Total Long-Term Liabilities $4.507M $0.00 $0.00
YoY Change 118183.46% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.012M $1.733M $1.970M
Total Long-Term Liabilities $4.507M $0.00 $0.00
Total Liabilities $8.518M $1.733M $1.970M
YoY Change 632.52% -12.02% 34.02%
SHAREHOLDERS EQUITY
Retained Earnings -$93.72M -$84.82M
YoY Change 18.94%
Common Stock $1.267K $61.60K
YoY Change -94.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.918M $26.49M $36.64M
YoY Change
Total Liabilities & Shareholders Equity $21.69M $28.23M $38.61M
YoY Change -7.56% -26.89% 217.54%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$9.847M -$1.696M -$3.015M
YoY Change -32.18% -43.74% 40.88%
Depreciation, Depletion And Amortization $302.4K $14.72K $317.5K
YoY Change -7.0% -95.36%
Cash From Operating Activities -$1.364M -$1.282M -$1.793M
YoY Change -12.92% -28.48% -1.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$3.170K -$75.67K
YoY Change -100.0% -95.81%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.01M -$70.07K
YoY Change -100.0% -14381.09% -800.7%
Cash From Investing Activities $0.00 $10.00M -$145.7K
YoY Change -100.0% -6964.0% -1557.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.323M 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.364M -1.282M -1.793M
Cash From Investing Activities 0.000 10.00M -145.7K
Cash From Financing Activities 4.323M 0.000 0.000
Net Change In Cash 2.959M 8.721M -1.939M
YoY Change 458.32% -549.89% 7.7%
FREE CASH FLOW
Cash From Operating Activities -$1.364M -$1.282M -$1.793M
Capital Expenditures $0.00 -$3.170K -$75.67K
Free Cash Flow -$1.364M -$1.279M -$1.717M
YoY Change -13.04% -25.52% -5.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
usd
CY2022Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001642375
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
us-gaap Increase Decrease In Due To Officers And Stockholders
IncreaseDecreaseInDueToOfficersAndStockholders
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
GHSI Noncash Adjust Warrant Liability
NoncashAdjustWarrantLiability
usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38861
dei Entity Registrant Name
EntityRegistrantName
GUARDION HEALTH SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4428421
dei Entity Address Address Line1
EntityAddressAddressLine1
2925 Richmond Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77098
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
873-5141
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
GHSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61600823 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12946003 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4093927 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
4995623 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1873743 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1411567 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1952931 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
367691 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1038439 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1200376 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
17811116 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12069184 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53763 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111378 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10363333 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11255833 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24257 usd
CY2022Q3 us-gaap Assets
Assets
28228212 usd
CY2021Q4 us-gaap Assets
Assets
23460652 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1040596 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
241347 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
683158 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
895477 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9472 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22221 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1733226 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1159045 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3807 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1733226 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1162852 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61600823 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61600823 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24426993 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24426993 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
61601 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24427 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111252019 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101075445 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84818634 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78802072 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26494986 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22297800 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28228212 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23460652 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2663550 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3148612 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8323382 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4605628 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1575366 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1760586 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4739197 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2558840 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
1088184 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
1388026 usd
us-gaap Gross Profit
GrossProfit
3584185 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
526193 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
777526 usd
us-gaap Gross Profit
GrossProfit
2046788 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60203 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16234 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
162418 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53598 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1583349 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1754321 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2231895 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3297725 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7875894 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8048713 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2103680 usd
CY2021Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
280176 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
280176 usd
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9287 usd
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-31883 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9287 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-31883 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2827578 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4403544 usd
us-gaap Operating Expenses
OperatingExpenses
9655205 usd
us-gaap Operating Expenses
OperatingExpenses
12272371 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1739394 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3015518 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6071020 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10225583 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
43282 usd
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
682 usd
us-gaap Interest Income Other
InterestIncomeOther
54458 usd
us-gaap Interest Income Other
InterestIncomeOther
934 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1696112 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3014836 usd
us-gaap Net Income Loss
NetIncomeLoss
-6016562 usd
us-gaap Net Income Loss
NetIncomeLoss
-10224649 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61600823 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24426993 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54196178 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23413055 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22297800 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
85963 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
59906 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
11585 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
8834899 usd
CY2022Q1 GHSI Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1134040 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2618487 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794121 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
61818 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-24011 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701963 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28141550 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
44101 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
5447 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1696112 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26494986 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8515266 usd
CY2021Q1 GHSI Cumulative Effect Adjustment
CumulativeEffectAdjustment
26265 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
205772 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
181843 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
33662597 usd
CY2021Q1 GHSI Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3568415 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2669525 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
43490633 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
183452 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
159640 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4540288 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39293437 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39293437 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
200005 usd
CY2021Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
164443 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3014836 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
36643049 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
36643049 usd
us-gaap Net Income Loss
NetIncomeLoss
-6016562 usd
us-gaap Net Income Loss
NetIncomeLoss
-10224649 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
946397 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
457782 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9287 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-31883 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
280176 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
191882 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
589229 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
76938 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
505926 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41679 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
457680 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1585240 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-205401 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
258560 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1017755 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-119579 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
799249 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76809 usd
GHSI Payments To Acquire Treasury Bills
PaymentsToAcquireTreasuryBills
77591741 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
260911 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-16556 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-120839 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-212319 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
440822 usd
us-gaap Increase Decrease In Due To Officers And Stockholders
IncreaseDecreaseInDueToOfficersAndStockholders
-148958 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6082906 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9078172 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5569 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
26036102 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4990054 usd
GHSI Payments To Acquire Treasury Bills
PaymentsToAcquireTreasuryBills
62975823 usd
GHSI Proceeds From Sale Of Treasury Bills
ProceedsFromSaleOfTreasuryBills
82587364 usd
GHSI Proceeds From Sale Of Treasury Bills
ProceedsFromSaleOfTreasuryBills
55981015 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33107719 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8834899 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33662599 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1134040 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3568414 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
24011 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9944928 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37231013 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8852076 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4954878 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4093927 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8518732 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12946003 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3563854 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
20844 usd
GHSI Noncash Adjust Warrant Liability
NoncashAdjustWarrantLiability
25978 usd
us-gaap Net Income Loss
NetIncomeLoss
-6016562 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6082906 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
12946003 usd
CY2022Q3 GHSI Working Capital
WorkingCapital
16077890 usd
CY2022Q1 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
CY2022Q3 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2022Q3 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
CY2022Q3 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 segment
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 segment
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-six (1:6) reverse stock split
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zZdHzaTefZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z33FTABu5pye">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2663550 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3148612 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8323382 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4605628 usd
CY2022Q3 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
1876259 usd
CY2021Q3 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
4951259 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
1932967 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
2560487 usd
CY2022Q3 us-gaap Advertising Expense
AdvertisingExpense
385010 usd
CY2021Q3 us-gaap Advertising Expense
AdvertisingExpense
513701 usd
us-gaap Advertising Expense
AdvertisingExpense
1264740 usd
us-gaap Advertising Expense
AdvertisingExpense
1203421 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zoMfM2QgT7ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zklhFNa7TYLd">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue. </i>During the three months ended September 30, 2022, the Company had one customer that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zJEDrDtPKMj3">57</span>% of total revenue. During the three months ended September 30, 2021, the Company had two customers that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z4TMsTXPWLzb">49</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zPHi9clursL6">10</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_z5NIv9IRG6K9"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_z3Lza4do7oDj">10</span></span>% of revenue<span style="background-color: white">, </span>during the three months ended September 30, 2022 and 2021. The Company sells the majority of its products to one of the largest retailers in the United States. Activ has been selling to this retailer for several years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company had one customer that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zG0Z8kNnKrZ3" title="Concentration Risk, Percentage">56</span>% of total revenue. During the nine months ended September 30, 2021, the Company had two customers that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zcMQUjIp1Ce5" title="Concentration Risk, Percentage">42</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zEiQLW1MyaMf" title="Concentration Risk, Percentage">10</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zg12UhNQNgvd"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zmkHTP2LqEq7">10</span></span>% of revenue<span style="background-color: white">, </span>during the nine months ended September 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts receivable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022<span style="background-color: white">, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zhIa1x77NwBa" title="Concentration Risk, Percentage">63</span>% of its accounts receivable. As of </span>December 31, 2021<span style="background-color: white">, the Company had accounts receivable from two customers which comprised approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zTOBfZ9azl99" title="Concentration Risk, Percentage">50</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z15mJ4qJeSNj" title="Concentration Risk, Percentage">48</span>% of its accounts receivable. No other customer accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_ztMLQITGXGue" title="Concentration Risk, Percentage"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zmILF2fLC99" title="Concentration Risk, Percentage">10</span></span>% of accounts receivable as of </span>September 30, 2022 <span style="background-color: white">and December 31, 2021. Historically the Company has not experienced any collectability issues with this customer.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Purchases from vendors</i>. During the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">three months and nine months ended September 30, 2022<span style="background-color: white">, the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zxa4Unmp3If" title="Concentration Risk, Percentage">49</span>% of all purchases during the three months ended September 30, 2022. There was one other vendor during the three months ended </span>September 30<span style="background-color: white">, 2022 that accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember_zomfMHSt6PK">12</span>% of total purchases. During the </span>three months ended September 30, 2021<span style="background-color: white">, the Company’s largest vendor accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zx2P6xYjblFe" title="Concentration Risk, Percentage">38</span>% of all purchases. During the nine months ended September 30, 2021, the Company’s largest vendors accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zSNQhGnP2fY1" title="Concentration Risk, Percentage">16</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zRUshG75hsyh">15</span>% of all purchases. No other vendor accounted for more than <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zUpKtvP20pA2"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zcWvQTnTprte"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zTYJK4G2AApj"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zHL6eY8bB7kh">10</span></span></span></span>% of purchases during the </span>three months and nine months ended September 30, 2022 <span style="background-color: white">and 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts payable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022<span style="background-color: white">, one vendor accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zTPk93mFe31b" title="Concentration Risk, Percentage">88</span>% of total accounts payable. As of </span>December 31, 2021, <span style="background-color: white">the Company’s largest two vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zqI2T8S8KB94" title="Concentration Risk, Percentage">18</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z5lqT3e9LiSg" title="Concentration Risk, Percentage">13</span>% of the total accounts payable. No other vendor accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zWJoc6EspAXb" title="Concentration risk, percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zF4oDWvqnBHd" title="Concentration risk, percentage">10</span></span>% of accounts payable as of </span>September 30, 2022 <span style="background-color: white">and December 31, 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12917044 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75241910 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1504829 shares
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
4995623 usd
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
26265 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3148612 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
10138421 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3014836 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7726233 usd
CY2021Q3 GHSI Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.12
GHSI Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.31
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
49699 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
53320 usd
CY2022Q3 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
1903232 usd
CY2021Q4 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
314371 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1952931 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
367691 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
176290 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
247705 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
122527 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
136327 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53763 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111378 usd
CY2022Q3 us-gaap Depreciation
Depreciation
14717 usd
CY2021Q3 us-gaap Depreciation
Depreciation
20008 usd
us-gaap Depreciation
Depreciation
53897 usd
us-gaap Depreciation
Depreciation
61115 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
50923 usd
GHSI Removal Of Depreciation
RemovalOfDepreciation
41636 usd
us-gaap Payments For Rent
PaymentsForRent
22991 usd
us-gaap Payments For Rent
PaymentsForRent
132002 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24257 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26028 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
16556 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9472 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9287 usd
CY2022Q3 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
9200000 usd
CY2021Q4 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
9200000 usd
CY2022Q3 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2700000 usd
CY2021Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2700000 usd
CY2022Q3 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
50000 usd
CY2021Q4 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
50000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11950000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11950000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1586667 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
694167 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10363333 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11255833 usd
CY2021Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
297500 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
892500 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
297500 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
396667 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
297500 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1190000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1190000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1190000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1190000 usd
CY2022Q3 GHSI Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
5255832 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10313332 usd
CY2022Q3 us-gaap Payments For Rent
PaymentsForRent
6884 usd
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
44548 usd
CY2022Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.039 pure
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5739 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3826 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9565 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
93 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9472 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9472 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
74485067 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
853088 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
66668 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.15
GHSI Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
100102 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
96144 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
723510 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.26
GHSI Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P6Y2M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
540552 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
723510 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
540552 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
66668 shares

Files In Submission

Name View Source Status
ghsi-20220930_cal.xml Edgar Link unprocessable
0001493152-22-031624-index-headers.html Edgar Link pending
0001493152-22-031624-index.html Edgar Link pending
0001493152-22-031624.txt Edgar Link pending
0001493152-22-031624-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ghsi-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
ghsi-20220930_def.xml Edgar Link unprocessable
ghsi-20220930_pre.xml Edgar Link unprocessable
ghsi-20220930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable